Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$20.25 +0.1%	$21.64	$19.00 ▼ $26.58	$2.48B	0.7	1.32 million shs	1.02 million shs
KALV KalVista Pharmaceuticals	$12.81 -4.0%	$13.44	$7.30 ▼ $16.32	$639.91M	0.05	788,673 shs	595,438 shs
KNSA Kiniksa Pharmaceuticals International	$33.15 -1.7%	$29.43	$17.82 ▼ $34.55	$2.46B	0.14	692,510 shs	371,536 shs
OGN Organon & Co.	$9.24 -0.5%	$9.74	$8.01 ▼ $23.10	$2.40B	0.6	4.51 million shs	3.86 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	+2.79%	-3.80%	-18.03%	+1.81%
KALV KalVista Pharmaceuticals	+3.57%	+6.63%	-13.32%	+8.99%	+11.17%
KNSA Kiniksa Pharmaceuticals International	+1.02%	+2.99%	+16.20%	+26.29%	+29.69%
OGN Organon & Co.	-1.70%	+2.98%	-2.01%	+6.06%	-54.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.917 of 5 stars	3.6	1.0	0.0	3.9	4.0	3.3	3.8
KALV KalVista Pharmaceuticals	4.0711 of 5 stars	3.6	1.0	0.0	4.4	3.2	1.7	0.6
KNSA Kiniksa Pharmaceuticals International	2.5628 of 5 stars	2.5	3.0	0.0	0.0	3.2	3.3	0.6
OGN Organon & Co.	4.6992 of 5 stars	3.3	2.0	1.7	3.7	3.5	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.29	Buy	$33.20	63.95% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	105.20% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	24.18% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	94.91% Upside

Current Analyst Ratings Breakdown

Latest KALV, CPRX, OGN, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$558.50M	4.44	$2.45 per share	8.27	$6.10 per share	3.32
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.80	N/A	N/A	$6.60 per share	5.02
OGN Organon & Co.	$6.40B	0.37	$4.81 per share	1.92	$1.83 per share	5.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.27	9.51	0.82	37.36%	40.78%	35.36%	11/5/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	828.96	132.60	N/A	0.90%	1.05%	0.80%	11/4/2025 (Estimated)
OGN Organon & Co.	$864M	$2.69	3.43	2.47	0.98	11.15%	163.88%	6.99%	10/30/2025 (Estimated)

Latest KALV, CPRX, OGN, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.87%	N/A	2.97%	N/A

Latest KALV, CPRX, OGN, and KNSA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.16
OGN Organon & Co.	11.98	1.65	1.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
KALV KalVista Pharmaceuticals	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
KALV KalVista Pharmaceuticals	10.50%
KNSA Kiniksa Pharmaceuticals International	53.48%
OGN Organon & Co.	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	74.11 million	34.48 million	Optionable
OGN Organon & Co.	4,000	259.97 million	256.33 million	Not Optionable

KALV, CPRX, OGN, and KNSA Headlines

Recent News About These Companies

Organon & Co. (NYSE:OGN) Shares Sold by Brandywine Global Investment Management LLC

August 18 at 5:55 AM | marketbeat.com

Russell Investments Group Ltd. Sells 128,059 Shares of Organon & Co. (NYSE:OGN)

August 18 at 4:51 AM | marketbeat.com

Vanguard Group Inc. Sells 699,976 Shares of Organon & Co. (NYSE:OGN)

August 17 at 3:36 AM | marketbeat.com

Organon & Co. (NYSE:OGN) Shares Purchased by KLCM Advisors Inc.

August 16 at 8:30 AM | marketbeat.com

There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings

August 15, 2025 | finance.yahoo.com

LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN)

August 15, 2025 | marketbeat.com

Public Sector Pension Investment Board Has $12.16 Million Position in Organon & Co. (NYSE:OGN)

August 14, 2025 | marketbeat.com

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

August 13, 2025 | prnewswire.com

Organon: Valuation Discount Offset By Structural Headwinds

August 12, 2025 | seekingalpha.com

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

August 12, 2025 | zacks.com

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend

August 11, 2025 | finance.yahoo.com

OGN vs. HQY: Which Stock Is the Better Value Option?

August 8, 2025 | zacks.com

Organon & Co. (NYSE:OGN) Given Average Recommendation of "Moderate Buy" by Brokerages

August 8, 2025 | marketbeat.com

Organon & Co. to Issue Quarterly Dividend of $0.02 (NYSE:OGN)

August 7, 2025 | marketbeat.com

Organon & Co. (OGN) Reports Q2 2025 Results

August 7, 2025 | insidermonkey.com

Organon & Co. Earnings Call: Resilience Amid Challenges

August 7, 2025 | theglobeandmail.com

Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

August 7, 2025 | finance.yahoo.com

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

August 6, 2025 | seekingalpha.com

Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings

August 6, 2025 | msn.com

Organon & Co. (NYSE:OGN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

August 6, 2025 | marketbeat.com

Organon & Co. (NYSE:OGN) Trading Down 9.4% - Here's Why

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, CPRX, OGN, and KNSA Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.25 +0.02 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$20.08 -0.17 (-0.84%)

As of 05:31 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

KalVista Pharmaceuticals NASDAQ:KALV

$12.81 -0.53 (-3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$12.80 -0.01 (-0.04%)

As of 04:25 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$33.15 -0.57 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$33.15 0.00 (0.00%)

As of 05:16 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Organon & Co. NYSE:OGN

$9.24 -0.05 (-0.48%)

Closing price 03:59 PM Eastern

Extended Trading

$9.26 +0.03 (+0.32%)

As of 05:24 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time